A Phase 4 interventional study of Remimazolam in Effect of Drug, sponsored by Tongji Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Tongji Hospital · Phase 4, Interventional, and Treatment
Exploring the ED90 of remimazolam in Drug-induced Sleep Endoscopy in adults at different BMI groups.
Exploring the ED90 of remimazolam in Drug-induced Sleep Endoscopy in adults at different BMI groups, to provide a more scientific medication scheme for sedation in Drug-induced Sleep Endoscopy.
Tongji Hospital is the lead sponsor of 373 studies on the registry; 204 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
BMI: ≥18.5 and \<24
Drug: Remimazolam
BMI: ≥24 and \<30
Drug: Remimazolam
BMI: ≥30
Drug: Remimazolam
Exploring ED90 induced by remimazolam anesthesia in adults of different BMI groups undergoing drug-induced sleep endoscopy
Also known as: Remimazolam besylate
Ramsey Sedation Scale
Using the Ramsey Sedation Scale scoring table ranging from 1-6 to evaluate if the sedation is successful 1point: Patients are anxious, restless or irritable; 2point: Patients cooperative, well-oriented and quiet; 3point: Patients fall asleep and respond only to commands; 4point: Patients fall asleep and respond quickly to eyebrow taps or loud auditory stimuli; 5point: Patients fall asleep and are blunt to respond to eyebrow taps or loud auditory stimuli; 6point: Patients fall asleep and do not respond to the above stimuli.
Time frame: 1 day
Time records
Anesthesia time, induction time, surgical time, awakening time and recovery time
Time frame: 1 day
Use of drugs
The total amount of sedative and analgesic drugs used.
Time frame: 1 day
Respiratory suppression incidence
Respiratory frequency\<8 times/min or SP02\<90%
Time frame: 1 day
Incidence of Treatment-Emergent Adverse Events
Intraoperative blood pressure and heart rate changes: record the patient's intraoperative blood pressure, heart rate, and the use of related vasoactive drugs; Postoperative adverse reactions: such as hypertension, hypotension, tachycardia, gastrointestinal symptoms, postoperative restlessness, etc.
Time frame: 2 days
Incidence of PACU Adverse Reactions
Nausea and vomiting, pain (VAS score), hypotension, bradycardia, dizziness;
Time frame: 1 day
Plan to share: No — You can request it from the main researcher.
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tongji Hospital